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APCs are good targets for development of vaccine adjuvants or
immunotherapy.
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Open access undRenal impairment and anemia during triple therapyTo the Editor:
We read with great interest the recently published review by
Romero-Gòmez and colleagues concerning the management of
anemia induced by triple therapy in patients with chronic hepa-
titis C [1]. In their work, authors thoroughly discuss about path-
ophysiological mechanisms responsible for the anemia observed
during triple therapy with telaprevir or boceprevir, remark base-
line and on-treatment factors predictive of more severe anemiza-
tion, and propose a sequential strategy to manage anemia based
ﬁrst on ribavirin dose reduction and then on epoetin administra-
tion. We strongly agree with the authors that anticipation of
anemia, which is based mainly on the knowledge of predictive
factors, is among the essential requisites for a tailored approach
to patient monitoring and management. In this regard, we
consider that the issue of a possible renal impairment during tri-
ple therapy with telaprevir or boceprevir, which is associated
with a more severe degree of anemia, deserved to be mentioned
in an updated review on this item. Indeed, simultaneously or
right after the publication of the work by Romero-Gòmez et al.,
several papers have been published concerning a possible renal
impairment during triple therapy with telaprevir or boceprevirJournal of Hepatologer CC BY-NC-ND license.[2–5]. While a decline of renal function was not reported as a
safety issue in clinical trials with any of the two drugs [6–9],
cases of renal failure were ﬁrstly signaled in the French early
access program [10]. More recently, in a large cohort of patients
undergoing triple therapy, Mauss et al. reported a week 12 inci-
dence of renal insufﬁciency stage 3, i.e., estimated glomerular ﬁl-
tration rate (eGFR) <60 ml/min, of 6.6% in patients treated with
telaprevir and of 4.7% in patients treated with boceprevir [2].
Patients with a drop of eGFR <60 ml/min had a higher absolute
decrease in hemoglobin and a lower week 12 hemoglobin level
[2]. Independently from the development of overt renal failure,
Kapelusznik et al. reported a mean maximal change of eGFR of
22 ml/min with respect to baseline in a group of 72 patients
analyzed at different time points during triple therapy with boce-
previr [3], Fukuda et al. observed a rapid decline of eGFR in 25
patients in triple therapy with telaprevir [baseline: 84.8, week
1: 69.9 ml/min, p <0.001] [4], and Karino et al. reported an almost
identical mean drop of eGFR at week 1, which was substantially
stable at the subsequent time points, in 68 patients in triple
therapy with telaprevir [baseline: 85.8, week 1: 69.6, week 4:
69.2, week 12: 72.5 ml/min] [5]. In the latter study, at week 1,y 2014 vol. 60 j 1097–1103 1099
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Letters to the Editor
there was a signiﬁcant positive correlation between delta eGFR
and ribavirin serum concentration, and the ribavirin serum con-
centration at week 1 was negatively correlated with the Hb levels
from week 2 to week 8 [5]. Although the exact mechanisms are
still not completely understood, all together, these data suggest
that telaprevir and boceprevir can impair renal function early
in the course of triple therapy for hepatitis C infection, and that
this impairment can lead to ribavirin accumulation and can
explain, at least in part, the higher rates of anemia observed in
triple vs. double therapy. On the base of these evidences, we think
that renal function should be assessed not only before, as already
recommended, but also early after the beginning of triple therapy
(1–2 weeks), that those patients experiencing a decline of eGFR
should be strictly monitored, and that an early reduction of
ribavirin dose should be strongly considered at least in patients
experiencing a reduction of eGFR to <60 ml/min.
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To the Editor:
We appreciate the comment by Vespasiani-Gentilucci et al. about
renal impairment and anemia during hepatitis C treatment with
protease inhibitors. We agree with the authors that renal impair-
ment is a growing concern in these patients, although the preva-
lence of estimated glomerular ﬁltration rate (eGFR) <60 ml/min
does not seem to be signiﬁcantly high with these drugs (6.6%
with boceprevir and 4.7% with telaprevir [1]). Additionally to pro-
tease inhibitors, older age, arterial hypertension, high baseline
serum creatinine as well as type 2 diabetes mellitus were found
to be associated with anemia [2]. Probably, the link between
these factors and anemia is the appearance of renal impairment
[3]. Indeed, the mechanisms involved in renal impairment with
protease inhibitors remain poorly understood. Signiﬁcant inhibi-
tion of some human renal drug transporters that could inﬂuence
ribavirin serum concentration has been described with telaprevir
[4]. This has been correlated with delta eGFR [5]. Telaprevir
though has shown an acceptable tolerability in haemodialyzed
patients who were listed for kidney transplantation, managing
successfully anemia with erythropoietin and ribavirin dose
reductions [6]. On the other hand, mean boceprevir concentration
1100 Journal of Hepatology 20[3] Kapelusznik L, Majid AM, Cox ER, Funk E, Flores Y, Charon B, et al. Boceprevir
is associated with a decline in renal function in a cohort of HCV-treated
patients. J Hepatol 2013;58:s342.
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was comparable in patients with end-stage renal disease and in
healthy subjects [7]. In conclusion, there is a mild risk of renal
insufﬁciency stage 3 with protease inhibitors that could be
responsible, at least in part, of the anemia that develops during
triple therapy. Thus, renal function should be closely monitored
to anticipate the appearance of anemia.
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